Evolve Capital Share Discussion Threads

[welshgoat2] 28/10/2010 13:17

It is expected that 3D's admission onto AIM ("Admission") will become effective
and dealings in its enlarged share capital will commence on 22 November 2010.
The market capitalisation of 3D, based upon the placing price of 6p per share,
will be GBP10.23 million. The closing mid-market price of 3D on 27 October 2010
was 10p per share. Following Admission Evolve will hold 53,974,354 ordinary
shares in 3D equivalent to 31.66% of its enlarged issued share capital.

[solaking] 28/10/2010 13:13

welshgoat,
thanks for that.
this may sound stupid. but there is no where that Evolve implied that they want to rto into 3D imaging in that news. or am i getting something wrong/not understanding it? although i know EVOL has 31.66% of 3D.
are they coming to AIM so that EVOL can rto into them? or has EVOL had any statement in the past that implied that? please help...
also if it is an rto, why would 3D bother raising capital instead of letting EVOL do all that work? can you see where i am coming from, or am i just "brain-dead" in understanding/interpreting this?
cheers, SK.

[welshgoat2] 28/10/2010 12:42

Evolve Capital plc
("Evolve" or the "Company")

Proposed Admission of Investee Company to trading on AIM

The Board of Evolve are pleased to note yesterday's announcement by 3D
Diagnostic Imaging plc ("3D"), a PLUS-quoted company in which Evolve has a
substantial investment, that it has conditionally raised GBP2.71 million (before
expenses) by way of a placing of 45,248,318 shares at a price of 6p per share
and that it intends to move from PLUS-quoted onto AIM.

It is expected that 3D's admission onto AIM ("Admission") will become effective
and dealings in its enlarged share capital will commence on 22 November 2010.
The market capitalisation of 3D, based upon the placing price of 6p per share,
will be GBP10.23 million. The closing mid-market price of 3D on 27 October 2010
was 10p per share. Following Admission Evolve will hold 53,974,354 ordinary
shares in 3D equivalent to 31.66% of its enlarged issued share capital.

A copy of 3D's admission document is available at the offices of 3D's lawyers,
Marriott Harrison, and further information on the company is available at
www.3ddiagnosticimaging.com.

Oliver Vaughan, Evolve's Chairman, commented:

"The Board believe that 3D is an excellent example of Evolve's wider business
model. We have supported the company from the outset and are delighted with the
progress that it has made to date. We look forward to further exciting
developments in the future."

[solaking] 28/10/2010 12:36

hi welshgoat2,
if you don't mind me asking, where did you get info that rto is being proposed? with who? which sector?
don't get me wrong, a company with mkt cap. less than its cash balance & asset is fantastic but i am trying to get my head around this quick so that i can decide. seems they started in PLUS according to beginning of this thread back in 2007, am i right? if yes, when did they move to AIM market?
any help/info will do.
cheers, SK.

[welshgoat2] 28/10/2010 12:34

mkt cap £3.5m cash £7m

[welshgoat2] 28/10/2010 12:17

rto proposed more cash than mkt cap.

[targatarga] 28/1/2009 09:32

looks like the evolve board need to buck up their act...

[topvest] 30/12/2007 19:16

If there was ever evidence that Simon Bickles is starting to get PLUS (formerly Ofex) going then here it is. A c£5m IPO for a PLUS investment vehicle. Looks an interesting one to follow given that the founders of Corporate Synergy are behind this (i.e. Edward Vandyk and Oliver Vaughan). Not currently a holder, but will watch with interest.

Edward Vandyk has also set up a new corporate adviser in the name of Whim Gully.